A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 8, 2003, Pages 1015-1019

  Labenz, J ^a   Petersen, K U ^b   Rosch W ^c   Koelz, H R ^d  

^a Ev Jung Stilling Krankenhaus   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Nord West Hospital   (Germany)

^d TRIEMLI HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BENZODIAZEPINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR;

ARTICLE; BLEEDING; DATA ANALYSIS; DATA BASE; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-ULCER AGENTS; ANTICOAGULANTS; BENZIMIDAZOLES; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HUMANS; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0038368802     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01550.x     Document Type: Article

References (30)

1. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton-pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9(4): 363-78.
2. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): S21-5.
3. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31(1): 9-28.
4. Unge P, Andersson T. Drug Interactions with proton pump inhibitors. Drug Saf 1997; 16(3): 171-9.
5. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 18-26.
6. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
7. Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England; cohort studies. Br J Clin Pharmacol 2000; 50: 366-72.
8. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39(4): 295-309.
9. Klotz U. Das Interaktionspotential der Protonenpumpeninhibitoren. Verdauungskrankkheiten, Jahrgang 20 2002; 1: S26-31.
10. Simon WA, Büdingen C, Fahr S, Kinder B, Koske M. The H+.K+-ATPase inhibitor pantoprazole (BY1023/SK & F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991; 42(2): 347-55.
11. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34(6): 243-62.
12. McCarthy DM, McLaughlin T, Yazdani C, El Serag HB, Griffis DL. Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: a cohort study. Gastroenterology 2002; 122(4)(Suppl. 1): A210, Abstract S1345.
13. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56(23)(Suppl. 4): S11-7.
14. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998; 23(6): 403-16.
15. Ahmad S. Omeprazole-warfarin interaction [letter]. South Med J 1991; 84: 674-5.
16. Sutfin T, Balmer K, Boström H, Eriksson S, Höglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84.
17. Unge P, Svedberg L-E, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509-12.
18. Andersson T, Bredberg E, Naesdal I, Wilson I. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Phamacol 1998; 54: 399-404.
19. Duursema L, Müller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995; 39: 700-3.
20. Ehrlich A, Fuder H, Hartmann M, et al. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol 1996; 51: 277-81.
21. Donnellan CF, Dass S, Dunn F, Hull MA. Warfarin anti-coagulation controls in patients taking proton pump inhibitors. Gut 2002; 50(Suppl. 2): A237(Abstract).
22. Zech K, Steinijans VW, Huber R, Kolassa N, Radtke HW. Pharmacokinetics and drug interactions - relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34(Suppl. 1): S3-6.
23. Langman MJS. Which PPI? Gut 2001; 49: 309-10.
24. Petersen KU. Proton pump inhibitors: what is the merit of the later entries? Leber, Magen, Darm 1997; 27(2): 77-82.
25. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002; 3(3): 289-309.
26. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15 419-22.
27. Ngui JS, Chen Q, Shou M, et al. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4′- and 10-hydroxywarfarin. Drug Metab Dispos 2001; 29: 877-86.
28. Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24: 1081-7.
29. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-62.
30. Tröger U. Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 2002; 324: 1497.